Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00098293
Registration number
NCT00098293
Ethics application status
Date submitted
6/12/2004
Date registered
7/12/2004
Date last updated
9/10/2013
Titles & IDs
Public title
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects
Query!
Secondary ID [1]
0
0
A4001026
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MERIT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV-1
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Maraviroc + Zidovudine/Lamivudine
Treatment: Drugs - Efavirenz + Zidovudine/Lamivudine
Treatment: Drugs - Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Experimental: 1 -
Active comparator: 3 -
Experimental: 2 - Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
Treatment: Drugs: Maraviroc + Zidovudine/Lamivudine
maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Treatment: Drugs: Efavirenz + Zidovudine/Lamivudine
efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Treatment: Drugs: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 48
Query!
Primary outcome [2]
0
0
Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population
Query!
Assessment method [2]
0
0
Percentage of participants with viral load of less than 400 copies/mL and less than 50 copies/mL of HIV-1 RNA were not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
Query!
Timepoint [2]
0
0
Week 48
Query!
Secondary outcome [1]
0
0
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [2]
0
0
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Week 96
Query!
Secondary outcome [3]
0
0
Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96
Query!
Assessment method [3]
0
0
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.
Query!
Timepoint [3]
0
0
Baseline, Week 48, Week 96
Query!
Secondary outcome [4]
0
0
Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels
Query!
Assessment method [4]
0
0
TAD from baseline was calculated as area under the curve (AUC) of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose. Data not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
Query!
Timepoint [4]
0
0
Baseline up to Week 48 and Week 96
Query!
Secondary outcome [5]
0
0
Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96
Query!
Assessment method [5]
0
0
Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose.
Query!
Timepoint [5]
0
0
Baseline, Week 48, Week 96
Query!
Secondary outcome [6]
0
0
Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96
Query!
Assessment method [6]
0
0
Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose. Change from baseline in lymphocyte CD8 count at Week 48 and 96 was not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.
Query!
Timepoint [6]
0
0
Baseline, Week 48, Week 96
Query!
Secondary outcome [7]
0
0
Time to Virologic Failure
Query!
Assessment method [7]
0
0
Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up \[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL(2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL(2 consecutive visits);failure if level \>=400 copies/mL(2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.
Query!
Timepoint [7]
0
0
Week 48, Week 96
Query!
Secondary outcome [8]
0
0
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
Query!
Assessment method [8]
0
0
Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 48 visit. Treatment failure: discontinuation due to insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as last on treatment assessment.
Query!
Timepoint [8]
0
0
Baseline, time of failure through Week 48
Query!
Secondary outcome [9]
0
0
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96
Query!
Assessment method [9]
0
0
Number of participants per tropism status (R5, X4, DM, or NR/NP) at baseline and time of treatment failure analyzed through week 96 visit. Treatment failure defined as insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as BLQ. The assessment for time of treatment failure was defined as last on treatment assessment.
Query!
Timepoint [9]
0
0
Baseline, time of failure through Week 96
Query!
Secondary outcome [10]
0
0
Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96
Query!
Assessment method [10]
0
0
Phenotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) assessed at screening by Monogram Bioscience PhenoSense genotype (MBPSGT) assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Phenotypic resistance to maraviroc was assumed in maraviroc treatment failures with X4-using virus and in R5 maraviroc treatment failures using Monogram Bioscience PhenoSense Entry Assay. Phenotypic resistance to zidovudine, lamivudine, efavirenz and maraviroc at time of failure was summarized.
Query!
Timepoint [10]
0
0
Screening, time of failure through Week 48, Week 96
Query!
Secondary outcome [11]
0
0
Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96
Query!
Assessment method [11]
0
0
Genotypic resistance to NRTIs was assessed by identification of relevant mutations at screening using MBPSGT assay and repeated for all participants with HIV-1 viral load more than 500 copies/mL at treatment failure through week 48 and week 96. Following mutations associated with NRTIs were summarized at time of failure: Any zidovudine/lamivudine (Zid/Lam), Any thymidine analogue-associated mutation (TAM), methionine (M) to valine/isoleucine (V/I) substitution at residue (r) 184 (M184V/I), lysine (K) to arginine (R) substitution at residue 65 (K65R) and any other NRTI mutations.
Query!
Timepoint [11]
0
0
Screening, time of failure through Week 48, Week 96
Query!
Secondary outcome [12]
0
0
Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96
Query!
Assessment method [12]
0
0
Genotypic resistance: mutations at screening by MBPSGT assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Efavirenz mutation:lysine to aspargine at r103(K103N);tyrosine to cysteine/isoleucine at r181(Y181C/I);tyrosine to cysteine/leucine/histidine at r188(Y188C/L/H);glycine to alanine/serine at r190(G190A/S);valine to alanine to r106(V106A);leucine to isoleucine at r100(L100I);alanine to glycine at r98(A98G);lysine to glutamic acid at r101(K101E);valine to isoleucine at r108(V108I);proline to histidine at r225(P225H);methionine to leucine at r230(M230L).
Query!
Timepoint [12]
0
0
Screening, time of failure through Week 48, Week 96
Query!
Secondary outcome [13]
0
0
Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL at Week 48 and Week 96 by Overall Susceptibility Score (OSS) at Screening
Query!
Assessment method [13]
0
0
Association between baseline resistance and virological response was assessed as percentage of participants with HIV-1RNA levels less than 50 copies/mL by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility.
Query!
Timepoint [13]
0
0
Baseline, Week 48, Week 96
Query!
Eligibility
Key inclusion criteria
* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 2, 000 copies/mL
* A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential (WOCBP)
* Effective barrier contraception for WOCBP and males
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Suspected or documented active, untreated HIV-1 related opportunistic infection (OI) or other condition requiring acute therapy
* Treatment for an active opportunistic infection, or unexplained temperature >38.5 degrees Celsius for 7 consecutive days
* Prior treatment with efavirenz, zidovudine or lamivudine or with any other antiretroviral therapy for more than 14 days at any time
* Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up
* Lactating women, or planned pregnancy during the trial period
* Suspected primary (acute) HIV-1 infection
* Previous therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 30 days prior to randomization or the expected need for such therapy during the study period
* Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization
* Significantly elevated liver enzymes or cirrhosis
* Significant neutropenia, anemia or thrombocytopenia
* Malabsorption or an inability to tolerate oral medications
* Symptomatic postural hypotension or severe cardiovascular or cerebrovascular disease
* Certain medications
* Genotypic or phenotypic resistance to efavirenz, zidovudine or lamivudine
* X4- or dual/mixed-tropic virus or repeated assay failure
* Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
916
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Burwood
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Surrey Hills
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Wentworthville
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - Herston
Query!
Recruitment hospital [6]
0
0
Pfizer Investigational Site - Miami
Query!
Recruitment hospital [7]
0
0
Pfizer Investigational Site - Melbourne
Query!
Recruitment hospital [8]
0
0
Pfizer Investigational Site - North Fitzroy
Query!
Recruitment hospital [9]
0
0
Pfizer Investigational Site - South Yarra
Query!
Recruitment postcode(s) [1]
0
0
2134 - Burwood
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
2010 - Surrey Hills
Query!
Recruitment postcode(s) [4]
0
0
2145 - Wentworthville
Query!
Recruitment postcode(s) [5]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [6]
0
0
4220 - Miami
Query!
Recruitment postcode(s) [7]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [8]
0
0
3068 - North Fitzroy
Query!
Recruitment postcode(s) [9]
0
0
3141 - South Yarra
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
South Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Virginia
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Washington
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Provincia de Buenos Aires
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Provincia de Neuquen
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Ciudad de Buenos Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Ciudad de Buenos
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Provincia de Santa Fe
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Brussels
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Gent
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
RJ
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Alberta
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
British Columbia
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Manitoba
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Nova Scotia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Antella (FI)
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Brescia
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Milano
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Modena
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Roma
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Torino
Query!
Country [42]
0
0
Mexico
Query!
State/province [42]
0
0
Mexico City
Query!
Country [43]
0
0
Mexico
Query!
State/province [43]
0
0
Mexico D.F.
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Amsterdam
Query!
Country [45]
0
0
Netherlands
Query!
State/province [45]
0
0
Rotterdam
Query!
Country [46]
0
0
Netherlands
Query!
State/province [46]
0
0
Utrecht
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Bialystok
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Bydgoszcz
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Chorzow
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Gdansk
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Krakow
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Szczecin
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Warszawa
Query!
Country [54]
0
0
Puerto Rico
Query!
State/province [54]
0
0
Ponce
Query!
Country [55]
0
0
Puerto Rico
Query!
State/province [55]
0
0
Rio Piedras
Query!
Country [56]
0
0
Puerto Rico
Query!
State/province [56]
0
0
San Juan
Query!
Country [57]
0
0
South Africa
Query!
State/province [57]
0
0
Eastern Cape
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Free State
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Gauteng
Query!
Country [60]
0
0
South Africa
Query!
State/province [60]
0
0
KwaZulu Natal
Query!
Country [61]
0
0
South Africa
Query!
State/province [61]
0
0
Bloomfontein
Query!
Country [62]
0
0
South Africa
Query!
State/province [62]
0
0
Cape Town
Query!
Country [63]
0
0
South Africa
Query!
State/province [63]
0
0
Johannesburg
Query!
Country [64]
0
0
South Africa
Query!
State/province [64]
0
0
Pretoria North
Query!
Country [65]
0
0
South Africa
Query!
State/province [65]
0
0
Pretoria
Query!
Country [66]
0
0
South Africa
Query!
State/province [66]
0
0
Soweto, Johannesburg
Query!
Country [67]
0
0
Switzerland
Query!
State/province [67]
0
0
Basel
Query!
Country [68]
0
0
Switzerland
Query!
State/province [68]
0
0
Bern
Query!
Country [69]
0
0
Switzerland
Query!
State/province [69]
0
0
Genève
Query!
Country [70]
0
0
Switzerland
Query!
State/province [70]
0
0
Lugano
Query!
Country [71]
0
0
Switzerland
Query!
State/province [71]
0
0
St. Gallen
Query!
Country [72]
0
0
Switzerland
Query!
State/province [72]
0
0
Zürich
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Loth
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Birmingham
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Brighton
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Edinburgh
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
London
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
ViiV Healthcare
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Pfizer
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The goal of this study is to compare the safety and efficacy of maraviroc (UK-427,857) versus efavirenz, when each are combined with two other antiretroviral agents, in patients who are previously naive to antiretroviral therapy. This study will involve approximately 200 centers from around the world to achieve a total randomized subject population of 1071 subjects. Patients will be randomly assigned to one of three groups: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily), Maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily) or efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily). The study will enroll over approximately an 18 month period (5 months Phase 2b run-in, 13 months Phase 3) with 96 weeks of treatment. This may be extended for an additional 3 years depending on the results at 96 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 48 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24, 48 and 96. A computerized tomography (CT) scan will also be performed, at selected centers, at study entry and week 96. Patients will be asked to complete a symptom distress questionnaire at study entry, weeks 12, 24, 48 and 96.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00098293
Query!
Trial related presentations / publications
Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. MacInnes A, Lazzarin A, Di Perri G, Sierra-Madero JG, Aberg J, Heera J, Rajicic N, Goodrich J, Mayer H, Valdez H. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials. 2011 Jan-Feb;12(1):24-36. doi: 10.1310/hct1201-24. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, Rajicic N, Valdez H, Lederman MM. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One. 2010 Oct 6;5(10):e13188. doi: 10.1371/journal.pone.0013188. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00098293
Download to PDF